These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9741046)

  • 1. Dexfenfluramine in psychotic patients.
    Svacina S; Sonka J; Marek J
    Int J Eat Disord; 1998 Nov; 24(3):335-8. PubMed ID: 9741046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy.
    Christensen JD; Yurgelun-Todd DA; Babb SM; Gruber SA; Cohen BM; Renshaw PF
    Brain Res; 1999 Jul; 834(1-2):1-5. PubMed ID: 10407087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular changes after treatment with dexfenfluramine and yohimbine in obese women measured by thoracic electrical bioimpedance.
    Waluga M; Janusz M; Karpel E; Hartleb M; Nowak A
    Boll Chim Farm; 1999; 138(7):359-63. PubMed ID: 10597657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible thermogenesis with dexfenfluramine.
    Roongpisuthipong C; Panpakdee O; Boontawee A; Kulapongse S; Tanphaichitr V
    J Med Assoc Thai; 1999 Feb; 82(2):150-9. PubMed ID: 10087722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dietary manipulation on substrate flux and energy balance in obese women taking the appetite suppressant dexfenfluramine.
    Poppitt SD; Swann DL; Murgatroyd PR; Elia M; McDevitt RM; Prentice AM
    Am J Clin Nutr; 1998 Nov; 68(5):1012-21. PubMed ID: 9808216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis.
    Carvajal A; García del Pozo J; Martín de Diego I; Rueda de Castro AM; Velasco A
    Methods Find Exp Clin Pharmacol; 2000 Jun; 22(5):285-90. PubMed ID: 11031729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
    Enzi G
    Ter Arkh; 1997; 69(5):71-5. PubMed ID: 9235665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke.
    Derby LE; Myers MW; Jick H
    Br J Clin Pharmacol; 1999 May; 47(5):565-9. PubMed ID: 10336582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].
    Geyer G; Haidinger G; Francesconi M; Langmayr N; Prager R; Schoberberger R; Toplak H; von Kalckreuth G; Kunze M
    Acta Med Austriaca; 1995; 22(5):95-101; 104-9. PubMed ID: 8651045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity.
    Oleandri SE; Maccario M; Rossetto R; Procopio M; Grottoli S; Avogadri E; Gauna C; Ganzaroli C; Ghigo E
    J Endocrinol Invest; 1999 Feb; 22(2):134-40. PubMed ID: 10195381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disordered eating: a defense against psychosis?
    Hugo PJ; Lacey JH
    Int J Eat Disord; 1998 Nov; 24(3):329-33. PubMed ID: 9741045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taking things to heart.
    Hess MA
    J Am Diet Assoc; 2004 Jul; 104(7):1073; author reply 1073-4. PubMed ID: 15215760
    [No Abstract]   [Full Text] [Related]  

  • 13. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
    Swinburn BA; Carmichael HE; Wilson MR
    Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1033-40. PubMed ID: 8923161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography.
    Roldan CA; Gelgand EA; Decker P; Prasad A; Shively BK
    Am J Cardiol; 2002 Dec; 90(11):1269-73. PubMed ID: 12450616
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of dexfenfluramine in a weight loss program for obese infertile women.
    Galletly C; Clark A; Tomlinson L
    Int J Eat Disord; 1996 Mar; 19(2):209-12. PubMed ID: 8932560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

  • 18. Eating disorders in schizophrenia.
    Lyketsos GC; Paterakis P; Beis A; Lyketsos CG
    Br J Psychiatry; 1985 Mar; 146():255-61. PubMed ID: 3857097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women.
    Flechtner-Mors M; Ditschuneit HH; Yip I; Adler G
    Am J Clin Nutr; 1998 Apr; 67(4):611-5. PubMed ID: 9537607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological intervention: the antiobesity approach.
    Rissanen A
    Eur J Clin Invest; 1998 Sep; 28 Suppl 2():27-30. PubMed ID: 9777325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.